Treace Q3 Revenue Falls 4% to $48.3M, Adjusted EBITDA Turns Positive at $0.3M
TMCI has more than doubled off its 52-week low of $1.17.
Summary
Treace reported Q3 2026 revenue of $48.3 million, down 4% year over year, while narrowing its net loss 23% to $12.6 million and turning Adjusted EBITDA positive at $0.3 million. The company tightened full-year revenue guidance to $206-210 million and improved its Adjusted EBITDA loss outlook to $1.0-2.0 million.
Key Events · Earnings and Guidance · TMCI
-
Q3 Revenue Declines 4%
Revenue was $48.3 million versus $50.2 million a year earlier, driven by a mix shift toward lower-priced minimally invasive products and fewer bunion procedure kits sold; excluding stocking distributors, revenue grew mid-single digits.
-
Adjusted EBITDA Turns Positive
Adjusted EBITDA improved $2.9 million to $0.3 million from $(2.6) million, and net loss narrowed 23% to $(12.6) million, or $(0.19) per share, from $(16.3) million, or $(0.26) per share.
-
Guidance Narrowed and Improved
Full-year 2026 revenue guidance is now $206-210 million (from $204-212 million), and the Adjusted EBITDA loss outlook improved to $1.0-2.0 million from $3.0-5.0 million.
-
Liquidity and Cash Usage
Cash, cash equivalents and marketable securities totaled $39.8 million at September 30, 2026; year-to-date cash usage fell 53%, or $9.7 million, and the existing credit facility offers up to $115 million of additional borrowing capacity subject to conditions.
Analysis · TMCI · Industrial Applications And Services
Revenue declined 4% to $48.3 million, yet the company swung Adjusted EBITDA to a $0.3 million profit from a $2.6 million loss a year earlier and cut its net loss 23% to $12.6 million. Management also raised the low end of its Adjusted EBITDA guidance to a $1.0-2.0 million loss from $3.0-5.0 million and narrowed revenue guidance to $206-210 million. The key question is whether the cost-driven improvement is sustainable: cash and marketable securities stand at $39.8 million against a $56.3 million long-term debt balance, so the $115 million undrawn credit facility is the liquidity backstop if cash usage does not keep falling.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TMCI was trading at $4.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $271.8M. The 52-week trading range was $1.17 to $6.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.